Search Results - john+isaacs

14 Results

Sort By:

Mechanism-based 3rd Generation Quinoline-3-carboxamide HDAC4 Inhibitor for Metastatic Castration-resistant Prostate Cancer

Value Proposition:· Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)· HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC· Similar anti-cancer agents must be dosed at lower concentrations...

Published: 3/14/2025 | Inventor(s): John Isaacs, William Brennen, Emmanuel Akinboye

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Oncology

Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs

Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...

Published: 3/13/2025 | Inventor(s): Soren Christensen, John Isaacs, Samuel Denmeade

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Sequential Hormone Therapy to Improve Survival and Enhance Response to Immune Therapy in Men with Prostate Cancer

Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an unmet clinical need to overcome resistance to hormone...

Published: 3/14/2025 | Inventor(s): Samuel Denmeade, John Isaacs, Emmanuel Antonarakis, Sushant Kachhap, Mark Markowski

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities

Novel prodrug strategy to improve clinical use of cancer drugs

Unmet Need / Invention Novelty: Clinical translation of various has been limited due to poor solubility and toxicity for repurposed anti-cancer applications. There exists an unmet need to develop new strategies to overcome these limitations. Technical Details: Researchers at Johns Hopkins have developed a novel prodrug strategy to improve solubility...

Published: 3/14/2025 | Inventor(s): William Brennen, John Isaacs, Samuel Denmeade, Emmanuel Akinboye

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology

Human Serum Albumin-PSA proaerolysin Prodrug

UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...

Published: 3/13/2025 | Inventor(s): John Isaacs, Samuel Denmeade, William Brennen

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

R-3327-AT6.3

Unmet NeedThere is increasing evidence supporting that ‘loss of function’ of metastasis suppressor genes plays an important role in cancer metastases. To help identify metastasis suppressor genes on human chromosomes, Johns Hopkins researchers have transferred individual human chromosomes into metastatic rat prostate cancer cells. Technology OverviewTo...